At a glance
- Originator Sankyo
- Class Antihyperlipidaemics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 05 Dec 2003 No development reported - Preclinical for Hyperlipidaemia in Japan (unspecified route)
- 21 Jul 1997 Preclinical development for Hyperlipidaemia in Japan (Unknown route)
- 21 Jul 1997 New profile